01—Abstract
Summary
Summary of the 10-Q filed October 30, 2026. Cited figures are marked; the original filing is the authoritative source.
Regeneron Pharmaceuticals, Inc. reported strong financial results for the nine months ended September 30, 2026, with revenues reaching $13.01 billiona, a significant increase from $10.46 billion in the prior year period.
Net income also saw robust growth, reaching $3.97 billion compared to $3.66 billionb in the same period last year. This performance was driven by strong net product sales, particularly from EYLEA HD and Libtayo, and a substantial increase in collaboration revenue, notably from the Sanofi partnership. The company's strategic collaborations, including the significant amendment with Sanofi in October 2026, which includes an upfront payment of $1 billion and potential future milestone payments, continue to be key drivers of growth.
Despite ongoing legal proceedings and competitive pressures, especially for EYLEA, Regeneron demonstrates a healthy financial position and a robust pipeline. The balance sheet as of September 30, 2026, shows total assets of $44.4 billionc, an increase from $40.56 billion at the end of 2025, supported by healthy cash and cash equivalents and growing accounts receivable.
Stockholders' equity also increased, reflecting strong retained earnings and additional paid-in capital, despite significant share repurchases and dividend payments. The company generated substantial cash flow from operations, providing ample liquidity to fund its ongoing research and development activities, capital expenditures, and shareholder returns.
02—Key points
Key Highlights
- Total revenues for the nine months ended September 30, 2026, increased by 24% to $13.01 billion, up from $10.46 billion in the prior year period.
- Net income for the nine months ended September 30, 2026, rose to $3.97 billion, or $37.37 per diluted share, compared to $3.66 billion, or $33.61 per diluted share, in the same period last year.
- Collaboration revenue significantly increased, driven by the Sanofi partnership, which included a $1 billion upfront payment in October 2026 for new licensed products and potential future milestone payments up to $7 billion.
- EYLEA HD U.S. net product sales saw a substantial increase of 63% for the nine months ended September 30, 2026, compared to the prior year, partially offsetting the decline in EYLEA U.S. sales.
- Libtayo's global net product sales grew by 44% for the nine months ended September 30, 2026, compared to the prior year, indicating strong market uptake.
- The company returned significant capital to shareholders through share repurchases totaling $2.34 billion and dividends paid of $290.3 million during the first nine months of 2026.
- Total assets grew to $44.4 billion as of September 30, 2026, with cash and cash equivalents at $3.66 billion and marketable securities at $15.2 billion.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2026filed October 30, 2026Financial Statements
Q3 FY2026 against Q3 FY2025
| Line item | Q3 FY2026Q3 FY2025 | Change |
|---|---|---|
| Revenue | $5.12B$3.75B | +36.3% |
| R&D Expenses | $1.79B$1.48B | +21.7% |
| SG&A Expenses | $677.80M$657.80M | +3.0% |
| Operating Expenses | $3.07B$2.73B | +12.5% |
| Operating Income | $2.05B$1.03B | +99.5% |
| Net Income | $1.95B$1.46B | +33.5% |
| EPS (Basic) | $19.16$14.09 | +36.0% |
| EPS (Diluted) | $18.45$13.62 | +35.5% |
| Shares Outstanding (Basic) | 101.70M103.60M | −1.8% |
| Shares Outstanding (Diluted) | 105.60M107.20M | −1.5% |
05—Questions
Frequently Asked Questions
What is the primary driver of Regeneron's revenue growth in the first nine months of 2026?
Regeneron's revenue growth was primarily driven by a combination of strong net product sales, particularly EYLEA HD and Libtayo, and a significant increase in collaboration revenue. The Sanofi collaboration was a major contributor, including a substantial upfront payment received in October 2026 for new licensed products.
How is the competition impacting EYLEA sales, and what is Regeneron doing about it?
EYLEA sales in the U.S. have been negatively impacted by increased competition from biosimilars and the ongoing transition of patients to EYLEA HD. Regeneron is focusing on the growth of EYLEA HD, which saw significant sales increases, and is also seeking regulatory approval for a pre-filled syringe for EYLEA HD to potentially improve its market position. The company is actively engaged in patent litigation to defend its EYLEA intellectual property.
What is the significance of the expanded collaboration with Sanofi announced in October 2026?
The expanded collaboration with Sanofi is highly significant as it includes a $1 billion upfront payment and up to an additional $7 billion in potential milestone payments. This collaboration adds four new Regeneron-invented antibodies to the development and commercialization agreement, further strengthening the partnership and Regeneron's future revenue potential.
How is Regeneron managing its capital and returning value to shareholders?
Regeneron generated strong operating cash flow, enabling significant shareholder returns. The company repurchased approximately $2.34 billion of its common stock during the first nine months of 2026 and declared quarterly cash dividends of $0.94 per share. As of September 30, 2026, approximately $2.16 billion remained available under its share repurchase program.
06—Continue